4-(3,4-二氯苯基)-哌啶盐酸盐 | 99329-54-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(3,4-二氯苯基)-哌啶盐酸盐
• 中文别名: 4-(3,4-二氯苯基)哌啶
• 英文名称: 4-(3,4-dichlorophenyl)piperidine
• CAS: 99329-54-1
• 化学式: C₁₁H₁₃Cl₂N
• 分子量: 230.137
• InChiKey: IREIFEVUVSLMAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(3,4-二氯苯基)-哌啶盐酸盐 生成 4-(3,4-dichlorophenyl)piperidine hydrochloride
  参考文献：
  名称：

  WO2007/65655

  摘要：

  公开号：
• 作为产物：
  描述：

  3,4-二氯溴苯 在 potassium phosphate 、 四(三苯基膦)钯 、 palladium on activated charcoal 、 氢气 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 41.0h， 生成 4-(3,4-二氯苯基)-哌啶盐酸盐
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4-phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model

  摘要：

  New tetrahydropyridinyl and piperidinyl ethylamine derivatives were designed with hypothetical mapping on pharmacophore model generated from ligand-based virtual screening. The designed compounds were synthesized, and their inhibitory activities on T-type calcium channel were assayed using FDSS and patch-clamp assay. Among them, compounds 7b and 10b showed potent T-type calcium current blocking activity against Ca(v)3.1 (alpha(1G)) and Ca(v)3.2 (alpha(1H)) channel simultaneously. With hERG and pharmacokinetics studies, compounds 7b and 10b were evaluated for the antinociceptive effect on rat model of neuropathic pain. They were significantly effective in decreasing the pain responses to mechanical and cold allodynia induced by spinal nerve ligation. These results suggest that modulation of alpha(1G) and am subtype T-type calcium channels may provide a promising approach for the treatment of neuropathic pain. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.12.056

文献信息

• Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders
  申请人：Zhao Cunxiang

  公开号：US20050234046A1

  公开（公告）日：2005-10-20

  Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

  芳基磺酰胺和磺酰基化合物作为过氧化物酶体增殖激活受体的调节剂，包含它们的药物组合物，以及使用它们治疗疾病的方法被披露。
• Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
  作者：Xian Zhang、Yantao He、Sijiu Liu、Zhihong Yu、Zhong-Xing Jiang、Zhenyun Yang、Yuanshu Dong、Sarah C. Nabinger、Li Wu、Andrea M. Gunawan、Lina Wang、Rebecca J. Chan、Zhong-Yin Zhang

  DOI：10.1021/jm901645u

  日期：2010.3.25

  homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling. Gain-of-function SHP2 mutations are associated with Noonan syndrome, various kinds of leukemias, and solid tumors. Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy. We report a salicylic acid based combinatorial library approach

  Src homology-2 域包含蛋白酪氨酸磷酸酶-2 (SHP2) 在生长因子和细胞因子信号传导中起关键作用。功能获得性 SHP2 突变与 Noonan 综合征、各种白血病和实体瘤有关。因此，人们对 SHP2 作为抗癌和抗白血病治疗的潜在靶点有相当大的兴趣。我们报告了一种基于水杨酸的组合文库方法，旨在结合活性位点和附近独特的亚袋，以提高亲和力和选择性。文库的筛选导致鉴定出具有高效细胞活性的 SHP2 抑制剂 II-B08（化合物9）。化合物9阻断生长因子刺激的 ERK1/2 激活和造血祖细胞增殖，提供支持证据表明 SHP2 的化学抑制可能对抗癌和抗白血病治疗有治疗作用。与9复合的 SHP2 结构的 X 射线晶体学分析揭示了可用于获得更有效和选择性 SHP2 抑制剂的分子决定因素。
• Phenoxypropylamine compounds
  申请人：——

  公开号：US20020111358A1

  公开（公告）日：2002-08-15

  The present invention relates to a phenoxypropylamine compound of the formula (I) 1 wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously show selective affinity for and antagonistic activity against 5-HT 1A receptor, as well as 5-HT reuptake inhibitory activity, and can be used as antidepressants quick in expressing an anti-depressive effect.

  本发明涉及一种公式（I）中的苯氧丙胺化合物： 1 其中每个符号如说明书中所定义，其光学活性化合物或其药物可接受的盐及水合物，同时显示出对5-HT 1A 受体的选择性亲和力和拮抗活性，以及5-HT再摄取抑制活性，并且可以用作快速表达抗抑郁效果的抗抑郁药。
• Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease
  作者：Daniel W. Kneller、Hui Li、Stephanie Galanie、Gwyndalyn Phillips、Audrey Labbé、Kevin L. Weiss、Qiu Zhang、Mark A. Arnould、Austin Clyde、Heng Ma、Arvind Ramanathan、Colleen B. Jonsson、Martha S. Head、Leighton Coates、John M. Louis、Peter V. Bonnesen、Andrey Kovalevsky

  DOI：10.1021/acs.jmedchem.1c01475

  日期：2021.12.9

  acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins is crucial to battle coronavirus disease 2019 (COVID-19). SARS-CoV-2 main protease (Mpro) is an established drug target for the design of protease inhibitors. We performed a structure–activity relationship (SAR) study of noncovalent compounds that bind in the enzyme’s substrate-binding subsites S1 and S2, revealing structural, electronic

  开发针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 蛋白的小分子抗病毒药物对于对抗 2019 年冠状病毒病 (COVID-19) 至关重要。 SARS-CoV-2 主要蛋白酶 (M pro ) 是设计蛋白酶抑制剂的既定药物靶点。我们对与酶的底物结合亚位点 S1 和 S2 结合的非共价化合物进行了构效关系 (SAR) 研究，揭示了这些位点的结构、电子和静电决定因素。该研究以 M pro与 Mcule-5948770040（化合物1 ）复合的 X 射线/中子结构为指导，其中质子化状态直接可视化。采用虚拟现实辅助结构分析和小分子构建来生成1的类似物。体外酶抑制测定和室温 X 射线结构证明了化学修饰对 M pro抑制的影响，表明（1）维持抑制剂 P1 基团的正确几何形状对于保留与质子化的 His163 的氢键至关重要； (2)优选带正电荷的接头； (3) 亚位点 S2 更喜欢体积较小的适度电负性基团。
• Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines
  作者：Rita L. Civiello、Xiaojun Han、Brett R. Beno、Prasad V. Chaturvedula、John J. Herbst、Cen Xu、Charles M. Conway、John E. Macor、Gene M. Dubowchik

  DOI：10.1016/j.bmcl.2016.01.026

  日期：2016.2

  improved oral bioavailability, metabolic stability, and pharmacokinetic properties, lower molecular weight, structurally simpler piperidine and piperazine analogs of BMS-694153 were prepared. Several were found to have nM binding affinity in vitro. The synthesis and SAR of these substituted piperidine and piperazine CGRP antagonists are discussed.

  降钙素基因相关肽（CGRP）是一种强力神经肽，与偏头痛的病理生理有关。在寻求具有改善的口服生物利用度，代谢稳定性和药代动力学性质的CGRP拮抗剂的过程中，制备了BMS-694153的较低分子量，结构更简单的哌啶和哌嗪类似物。发现一些在体外具有nM结合亲和力。讨论了这些取代的哌啶和哌嗪CGRP拮抗剂的合成和SAR。